Overview
Pancreatic ductal adenocarcinoma (PDAC) complexity, where genetic, stromal, and immunological factors all interact with each other, is responsible for the overall poor response of PDAC to chemotherapeutic agents, making this a lethal disease. The investigators hypothesize that: (i) dissection of genetic, stromal, and immunological factors on endoscopic ultrasound fine needle biopsy (EUS-FNB) tissue samples from unresectable PDAC patients' will allow to determine prognostic factors in this patient population; (ii) treatment response and acquisition of tumor chemotherapy resistance could be related to genetic heterogeneity between the primary and metastatic sites and alteration of the molecular profile under drug' selection pressure.
Eligibility
Inclusion Criteria:
- Patients referred to EUS with FNB for suspected pancreatic cancer unresectable or metastatic based on imaging findings
- Availability of biopsies obtained during EUS-FNB
- Histological diagnosis of pancreatic ductal adenocarcinoma of any stage
- Patients must be fit for chemotherapy administration
- They have to express their willingness to be followed up at our pancreatic high volume centers
- Age \>18 and \<80 years
- Able to sign informed consent
Exclusion Criteria:
- Histological diagnoses other than pancreatic ductal adenocarcinoma
- Pregnancy or lactation
